Diagnostics
Filter News
Found 6,184 articles
-
Castle Biosciences to Release Second Quarter 2021 Financial Results and Host Conference Call on Monday, Aug. 9, 2021
7/26/2021
Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced that it will release its financial results for the second quarter and six months ended June 30, 2021, after the close of market on Monday, Aug. 9, 2021.
-
SpeeDx Launch Solution for SARS-CoV-2 Variant Analysis
7/26/2021
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have launched a new product line of research reagents to support reflex variant analysis for circulating SARS-CoV-2 variants of concern.
-
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in Canada
7/26/2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care with the quality of results expected of an automated platform, is now available in Canada.
-
Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck
7/23/2021
Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced a podium presentation on its DecisionDx®-SCC test at the American Head & Neck Society 10th International Conference on Head and Neck Cancer, being held July 22-25, 2021.
-
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industr...
-
For the past year, Abbott Laboratories and Quest Diagnostics saw their revenue driven by COVID-19 diagnostics, but that seems to be changing as more and more vaccinated individuals are seeking medical advice for non-viral related issues.
-
Co-Diagnostics, Inc. Strengthens Intellectual Property Portfolio with New International CoPrimer™ Patent
7/22/2021
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has added to its suite of intellectual property protection after being awarded a patent from the Republic of Korea's Intellectual Property Office for the Company's CoPrimer™ technology.
-
HTG Forms New Drug Discovery Business UnitNew unit to focus on development of drug candidates through use of HTG Transcriptome Panel
7/20/2021
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the creation of a new business unit, HTG Therapeutics.
-
Appointment of Fred S. Zeidman to the Board of Directors of Bluejay Diagnostics, Inc.
7/20/2021
Bluejay Diagnostics, Inc., announced that Mr. Fred S. Zeidman has been appointed to the Boards of Directors and Chairman of Nominating and Corporate Governance Committee of the Company.
-
Synergy Laboratories Hires Dr. Tyler Jones as New Pathologist
7/20/2021
Dr. Tyler Jones is a graduate of Brigham Young University in Provo, UT, and graduated medical school at Ross University School of Medicine.
-
Wellspring Capital-Backed RAYUS Radiology Acquires One Of The Largest Radiology Groups In The U.S., Bolstering Its Growing Nationwide Network
7/20/2021
RAYUS Radiology announces the acquisition of Foundation Radiology Group, a Pittsburgh-based, full-service radiology provider with more than 100 radiologists delivering on-site and tele-radiology services to more than 45 health systems, community hospitals, prominent academic medical centers and outpatient imaging facilities across seven states.
-
T2 Biosystems Reports Granting of Inducement Award - July 19, 2021
7/19/2021
T2 Biosystems, Inc. a leader in the rapid detection of sepsis-causing pathogens, announced that it issued inducement awards to eleven new employees.
-
State of Delaware Selects Quidel for COVID-19 Testing Program at Schools
7/19/2021
Quidel Corporation, a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it is entering a partnership with the State of Delaware to implement a full-service, turn-key COVID-19 testing program to support the reopening of K-12 schools in the fall through its new service provider, Quidel Services, LLC.
-
Castle Biosciences Expands its Board of Directors with New Appointments
7/16/2021
Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced that Kim Caple and Ellen Goldberg have been appointed to its board of directors, effective immediately.
-
PixCell Medical Appoints Armin Schon as New Chief Commercial Officer to Foster Continued HemoScreen™ Growth
7/15/2021
PixCell Medical, innovator of rapid diagnostic solutions at the point-of-care, announced today that Armin Schon, Ph.D., has been appointed chief commercial officer, effective immediately.
-
Novel Saliva Assay by Accure Health Tracks COVID-19 Vaccine Response in Proof-of-Concept Study
7/15/2021
Accure Health, a developer of rapid digital diagnostics, today announced the online publication of preliminary data showing that its novel saliva assay can assess individual immune response to COVID-19 vaccines, monitor neutralizing antibody levels over time, and model immune protection against SARS-Cov-2 variants.
-
Biofidelity Announces Formation of Scientific Advisory Board
7/15/2021
Biofidelity Ltd, the cancer diagnostics company, announces the members of its newly-formed Scientific Advisory Board with the appointments of leaders from the clinical, pharmaceutical and patient advocacy fields.
-
IncellDx: Two New Studies Offer a First Model for Diagnosing, Monitoring and Treating Long COVID
7/14/2021
Two new studies propose the first model for diagnosing, indexing and monitoring Post-Acute Sequelae of COVID-19 (PASC), also known as long COVID or long haul COVID.
-
NeoGenomics Schedules its Second Quarter 2021 Earnings Release for August 6, 2021
7/14/2021
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing and global contract research services, announced that it plans to release its second quarter 2021, financial results on Friday, August 6, 2021.
-
Avacta’s Diagnostic Division Achieves ISO 13485 Certification
7/14/2021
Avacta Group plc is pleased to announce that Avacta Life Sciences’ diagnostics division has achieved ISO 13485 certification for the quality management system for the manufacture and distribution of Affimer reagents for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.